基于肠道微生物托法纳酶的机制抑制降低了血清氧化硫酸的含量
Amanda L Graboski1, Mark E Kowalewski2, Joshua B Simpson3
1Department of Pharmacology, University of North Carolina, Chapel Hill, Chapel Hill, NC 27599, USA.
Cell chemical biology
|August 26, 2023
概括
研究人员开发了一种新型药物, (3S) ALG-05,用于抑制肠道微生物类酶. 这种药物有效地降低了酸,这是一种与慢性病进展和毒性相关的毒素.
科学领域:
- 微生物组研究的研究.
- 药品化学 药品化学 是一个
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 硫酸是慢性病 (CKD) 中的主要尿素毒素,有助于脏和心血管损伤.
- 肠道微生物托法纳酶会将醇代谢成氧硫酸,这是其致病的核心过程.
研究的目的:
- 为了识别和描述人类肠道微生物群中的型酶酶.
- 开发一种强效的非杀菌性抑制剂,向这些酶,以减少硫酸的产量.
主要方法:
- 在肠道微生物种群中对型酶同质性的生物信息分析.
- 药物化学运动设计和合成一个过渡状态模拟抑制剂, (3S) ALG-05.5.
- 在体外微生物培养和体内小鼠模型中评估抑制剂的有效性和毒性.
主要成果:
- 确定了肠道微生物类酶的保存结构和功能特征.
- (3S) ALG-05在具有低毒性的微生物培养物中显示出强烈抑制道产生的作用.
- 在体内给药 (3S) ALG-05 降低了小鼠的血清内氧硫酸和血清内氧硫酸水平.
结论:
- 一种新型泛抑制剂, (3S) ALG-05,有效地向肠道微生物的三甲酶.
- 这种非杀菌方法在治疗慢性病患者的氧硫酸水平方面显得有前途.
- 进一步开发 (3S) ALG-05可能为CKD并发症提供治疗策略.
相关概念视频
Irritable Bowel Syndrome I: Introduction
311
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
311
Gene Regulation in Microbial Communities: Quorum Sensing
39
Quorum sensing is a mechanism of bacterial communication that enables coordinated gene expression in response to changes in population density. This facilitates collective behaviors that enhance survival, resource acquisition, and ecological adaptation. This process relies on small signaling molecules called autoinducers that accumulate as bacterial populations grow. When a critical threshold concentration of autoinducers is reached, bacterial cells collectively modify gene expression,...
39
Repressible Operon: trp Operon
48
The trp operon in Escherichia coli exemplifies a repressible operon. It regulates the synthesis of tryptophan through repressor-mediated transcriptional control and attenuation. This dual regulatory mechanism ensures tryptophan biosynthesis occurs only when needed, conserving cellular resources.Structure of the trp OperonThe trp operon consists of five structural genes (trpE, trpD, trpC, trpB, and trpA) that encode enzymes for tryptophan biosynthesis. These genes are transcribed as a single...
48
Combined Effects of Drugs: Synergism
4.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.0K
Feedback Inhibition
54.0K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
54.0K
Inflammatory Bowel Disease IV: Pharmacological Management
152
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
152


